COVID-19 Response

The Oxford BioDynamics facility remains operational and is continuing to provide biomarker support for clinical trials worldwide during this challenging period.

EpiSwitch™ selected for prognostic and predictive profiling of COVID-19 patients. 

Read more…

Innovation Saving Lives

We are a biotechnology company with a proprietary epigenetic biomarker discovery platform, EpiSwitch™, based on the latest advances in regulatory genome architecture and its link to clinical outcomes and patient stratification.

EpiSwitch™ biomarkers based on chromosomal conformation signatures are a critical cog in personalised medicine.

Technology to select the right drug at the right dose at the right time for the right patient.

Our Publications on EpiSwitch™


Chromosome conformation signatures response to methotrexate in early rheumatoid arthritis.

Carini et. al.
J Transl Med
http://em.rdcu.be/wf/click?upn=KP7O1RED-2BlD0F9LDqGVeSNikQRdSSVno6y1sy5PiGtY-3D_1Xwc2qYR6TifXA9E6uiEHGOeyluJhvI-2BsoiymOjeLDmDhsgq-2BbJrS1iWyD4DsCokgw5J-2B3bme1wt9rQL1jPNrKEjzTH0bn6qR5ZNXKiFtMLgW49uGX8lHedANlmYJiPtQKetB85nI2-2Fygw2eFOzKryJU11Ig7fnQky06uGSbL0kRMmx3Z1UlRwvSOj4YhjgjUdPyQrXAe2DRsMlWr1e0dEbPhgYPENQKNTaKXZ2wEtkRxWvzZzrnDcvZjd3FAYgSy-2BurJe-2BZNifTHuR9l-2Fc8RlzWrudMdGVINHdvg1Y0uzw-3D

A chromosomal conformation signature for a priori prediction of ALS progression subtypes.

Salter, et. al.,
F1000 Research
http://dx.doi.org/10.7490/f1000research.1115185.1

Glycaemic progression study among population in Penang, Malaysia.

Patel, JS, et. al.,
Diabetes Asia 2017 Conference
http://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/Glycaemic-Progression-Study-Among-Population-in-Penang-Malaysia.pdf

A Prospective Study of Two Distinct Epigenetic Signatures for ALS Diagnosis and Prognosis.

Westra, W, et. al.,
16th Annual Northeast Amyotrophic Lateral Sclerosis Meeting
http://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/NEALS_2017_ALS_Biomarker.pdf

Epigenetic signatures and early detection of neurodegenerative diseases: Development of stratifying biomarker for ALS in Asian cohorts.

Lim, CR, et. al.,
World Congress of Neurology
https://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/ALSposter_WCN2017Kyoto_Final.pdf

PerkinElmer releases application note outlining the importance of EpiSwitch™ technology in determining epigenetic biomarkers using the LabChip GX Touch Platform.

OBD and PerkinElmer
Application Note; 25 August 2017
https://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/013589_01EpiGenetics-Biomarkers-APP.pdf

Super-Enhancers and Broad H3K4me3 Domains Form Complex Gene Regulatory Circuits Involving Chromatin Interactions.

Cao, F, et. al.,
Scientific Reports
https://www.nature.com/articles/s41598-017-02257-3

Chromatin Conformation Signatures Associated with Epigenetic Deregulation of the FIP1L1 and PDGFRA Genes.

Grand, FH, et. al.,
American Society of Haematology
https://ash.confex.com/ash/2016/webprogram/Paper90884.html

Epigenetic footprints for neurodegenerative and autoimmune conditions: a comparative analysis.

Hunter, E, et. al.,
The Lancet Neurology Conference
http://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/2016-LNC-Epigenetic-footprints-for-neurodegenerative-and-autoimmune-conditions.pdf

Epigenetic signatures and early detection of neurodegenerative diseases.

Salter, M., et. al.,
The Lancet Neurology Conference
http://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/2016-LNC-Epigenetic-signatures-and-early-detection-of-neurodegenerative-diseases.pdf